Literature DB >> 19144762

Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis.

Siribha Changsirikulchai1, David Myerson, Katherine A Guthrie, George B McDonald, Charles E Alpers, Sangeeta R Hingorani.   

Abstract

BACKGROUND AND OBJECTIVES: Thrombotic microangiopathy (TMA) is a known complication of hematopoietic cell transplantation (HCT). The etiology and diagnosis of TMA in this patient population is often difficult because thrombocytopenia, microangiopathic hemolytic anemia, and kidney injury occur frequently in HCT recipients, and are the result of a variety of insults. DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: The authors reviewed renal pathology and clinical data from HCT patients to determine the prevalence of TMA and to identify correlative factors for developing TMA in the kidney. Kidney tissue was evaluated from 314 consecutive autopsies on patients who died after their first HCT (received between 1992 and 1999). Renal pathology was classified into three groups: (1) no renal thrombus (65%), (2) TMA (20%), and (3) isolated thrombosis (15%). Logistic regression models estimated the associations between each histologic category and clinical parameters: donor and recipient gender, patient age, human leukocyte antigen (HLA) matching of the donor and recipient, total body irradiation (TBI), acute graft versus host disease (GVHD), acute kidney injury, medications, and viral infections.
RESULTS: In a multivariate analysis, TMA correlated with acute GVHD grades II to IV, followed by female recipient/male donor, TBI > 1200 cGy, and adenovirus infection. Grades II to IV acute GVHD and female gender were associated with isolated renal thrombus.
CONCLUSIONS: TMA in HCT recipients is associated with acute GVHD grades II to IV, recipient/donor mismatch, TBI > 1200 cGy, and adenovirus infection.

Entities:  

Mesh:

Year:  2009        PMID: 19144762      PMCID: PMC2637592          DOI: 10.2215/CJN.02070508

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  35 in total

1.  Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.

Authors:  Hirohisa Nakamae; Takahisa Yamane; Taro Hasegawa; Mika Nakamae; Yoshiki Terada; Kiyoyuki Hagihara; Kensuke Ohta; Masayuki Hino
Journal:  Am J Hematol       Date:  2006-07       Impact factor: 10.047

2.  Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation.

Authors:  C-K Min; S Y Kim; M J Lee; K S Eom; Y J Kim; H J Kim; S Lee; S G Cho; D W Kim; J W Lee; W S Min; C C Kim; C S Cho
Journal:  Bone Marrow Transplant       Date:  2006-06-05       Impact factor: 5.483

Review 3.  Bone-marrow transplantation (second of two parts).

Authors:  E D Thomas; R Storb; R A Clift; A Fefer; L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-24       Impact factor: 91.245

4.  Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants.

Authors:  M T Martinez; Ch Bucher; G Stussi; D Heim; A Buser; D A Tsakiris; A Tichelli; A Gratwohl; J R Passweg
Journal:  Bone Marrow Transplant       Date:  2005-12       Impact factor: 5.483

5.  von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura.

Authors:  R M van der Plas; M E Schiphorst; E G Huizinga; R J Hené; L F Verdonck; J J Sixma; R Fijnheer
Journal:  Blood       Date:  1999-06-01       Impact factor: 22.113

6.  De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection.

Authors:  J Waiser; K Budde; B Rudolph; M A Ortner; H H Neumayer
Journal:  Am J Kidney Dis       Date:  1999-09       Impact factor: 8.860

7.  Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.

Authors:  Corey Cutler; N Lynn Henry; Colm Magee; Shuli Li; Haesook T Kim; Edwin Alyea; Vincent Ho; Stephanie J Lee; Robert Soiffer; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2005-07       Impact factor: 5.742

8.  Adenovirus nephritis in hematopoietic stem-cell transplantation.

Authors:  Benedetto Bruno; Richard A Zager; Michael J Boeckh; Theodore A Gooley; David H Myerson; Meei-Li Huang; Robert C Hackman
Journal:  Transplantation       Date:  2004-04-15       Impact factor: 4.939

9.  VEGF inhibition and renal thrombotic microangiopathy.

Authors:  Vera Eremina; J Ashley Jefferson; Jolanta Kowalewska; Howard Hochster; Mark Haas; Joseph Weisstuch; Catherine Richardson; Jeffrey B Kopp; M Golam Kabir; Peter H Backx; Hans-Peter Gerber; Napoleone Ferrara; Laura Barisoni; Charles E Alpers; Susan E Quaggin
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

Review 10.  Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma.

Authors:  James N George; Xiaoning Li; Jay R McMinn; Deirdra R Terrell; Sara K Vesely; George B Selby
Journal:  Transfusion       Date:  2004-02       Impact factor: 3.157

View more
  48 in total

Review 1.  Acute kidney injury in hematopoietic cell transplantation.

Authors:  Amy Kogon; Sangeeta Hingorani
Journal:  Semin Nephrol       Date:  2010-11       Impact factor: 5.299

Review 2.  Acute kidney injury in HCT: an update.

Authors:  J A Lopes; S Jorge; M Neves
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

3.  Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.

Authors:  J Labrador; L López-Corral; O López-Godino; L Vázquez; M Cabrero-Calvo; R Pérez-López; M Díez-Campelo; F Sánchez-Guijo; E Pérez-López; C Guerrero; I Alberca; M C Del Cañizo; J A Pérez-Simón; J R González-Porras; D Caballero
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

4.  Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation.

Authors:  Jiaqian Qi; Jie Wang; Jia Chen; Jian Su; Yaqiong Tang; Xiaojin Wu; Xiao Ma; Feng Chen; Changgeng Ruan; X Long Zheng; Depei Wu; Yue Han
Journal:  Ann Hematol       Date:  2017-08-11       Impact factor: 3.673

5.  Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy?

Authors:  Sonata Jodele; Benjamin L Laskin; Jens Goebel; Jane C Khoury; Susan L Pinkard; Patricia M Carey; Stella M Davies
Journal:  Transfusion       Date:  2012-07-15       Impact factor: 3.157

Review 6.  Renal dysfunction following bone marrow transplantation.

Authors:  Stephan Kemmner; Mareike Verbeek; Uwe Heemann
Journal:  J Nephrol       Date:  2016-09-02       Impact factor: 3.902

7.  Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation.

Authors:  Merve Postalcioglu; Haesook T Kim; Faruk Obut; Osman Arif Yilmam; Jiqiao Yang; Benjamin C Byun; Sophie Kupiec-Weglinski; Robert Soiffer; Jerome Ritz; Joseph H Antin; Edwin Alyea; John Koreth; Corey Cutler; Philippe Armand; Julie M Paik; David E Leaf; Vincent T Ho; Reza Abdi
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-11       Impact factor: 5.742

8.  Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells.

Authors:  Sarah E Sartain; Nancy A Turner; Joel L Moake
Journal:  J Biol Chem       Date:  2018-03-19       Impact factor: 5.157

Review 9.  A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.

Authors:  Sonata Jodele; Benjamin L Laskin; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Stella M Davies; Jens Goebel; Bradley P Dixon
Journal:  Blood Rev       Date:  2014-11-28       Impact factor: 8.250

Review 10.  Post-bone marrow transplant thrombotic microangiopathy.

Authors:  F Obut; V Kasinath; R Abdi
Journal:  Bone Marrow Transplant       Date:  2016-03-14       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.